Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL INTENSOL versus PROCHLORPERAZINE EDISYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL INTENSOL versus PROCHLORPERAZINE EDISYLATE.
HALOPERIDOL INTENSOL vs PROCHLORPERAZINE EDISYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has moderate affinity for alpha-1 adrenergic receptors and low affinity for H1 histamine and muscarinic cholinergic receptors.
Prochlorperazine is a phenothiazine antipsychotic that antagonizes dopamine D2 receptors in the brain, particularly in the chemoreceptor trigger zone, exerting antiemetic effects. It also blocks alpha-adrenergic and muscarinic receptors.
Oral (Intensol): 0.5-5 mg twice or three times daily. Maximum: 100 mg/day.
Antiemetic: 5-10 mg IM/IV every 3-4 hours as needed, maximum 40 mg/day; or 25 mg PR twice daily. Antipsychotic: 10-20 mg IM/IV every 1-4 hours, maximum 40 mg/day; oral: 5-10 mg 3-4 times daily, maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14-37 hours (average 21 hours) after oral administration; may be longer in elderly or hepatic impairment.
Terminal elimination half-life is approximately 6-8 hours, but may be prolonged to 10-12 hours in elderly patients or those with hepatic impairment. In overdoses, half-life can extend beyond 24 hours.
Primarily hepatic metabolism with renal elimination of metabolites; about 40% excreted in urine and 15% in feces via bile.
Primarily renal excretion of metabolites (approximately 70-80% as conjugated metabolites), with less than 1% excreted unchanged. Fecal excretion accounts for about 20-30% via biliary elimination.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic